Necitumumab

Neoplasm

Eli Lilly and Companymonoclonal_antibodyPhase 2Dormant

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 65/ 100

Competitive context

890 Active assets in the Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Panitumumab Astellas Pharma Inc	Phase 2	BBB
Granulocyte Colony-Stimulating Factor Lenograstim Sanofi	Phase 4	BB
Dexmedetomidine Medical College of Wisconsin	Phase 4	BB
Lidocaine Medical College of Wisconsin	Phase 4	BB
Relatlimab Bristol-Myers Squibb	Phase 2	BB

View all 50 →

Same molecule, other indications

Necitumumab is also rated in:

non-small cell lung carcinomaActive

BBB

Indicative · Phase 3

76 / 100

non-small cell squamous lung carcinomaDormant

B

Indicative · Phase 2

57 / 100

squamous cell lung carcinomaDormant

CCC

Indicative · Phase 1/2

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.